Subtype
Colorectal Neoplasm
CI-CAN-00002404Explore in graph →
Non-malignant1,784 active trials21 approved drugs382 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002404Explore in graph →
Clinical trials
8,604 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05223673 | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer(COLSTAR) | terminated | Phase 3 | 7 | Institut de Recherches Internationales ServierOTHER | 6 | Aug 20, 2024 | clinicaltrials |
| NCT03866239 | A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma | terminated | Phase 1 | 47 | Hoffmann-La Roche |
| 4 |
| Aug 9, 2024 |
| clinicaltrials |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 30 | Biosplice Therapeutics, Inc.INDUSTRY | 2 | Aug 9, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors | terminated | Phase 1 | 37 | PfizerINDUSTRY | 1 | Jul 29, 2024 | clinicaltrials |
| NCT05039944 | SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies | terminated | Phase 2 | 7 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT01855607 | Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy | terminated | Phase 2 | 12 | Columbia UniversityOTHER | 1 | Jul 11, 2024 | clinicaltrials |
| NCT02842580 | De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer(HIGH-LIGHT) | terminated | Phase 2 | 21 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT05769959 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | terminated | Phase 1 | 3 | Hoffmann-La RocheINDUSTRY | 1 | Jul 9, 2024 | clinicaltrials |
| NCT03631641 | Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy | terminated | Phase 2 | 3 | John HaysOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT02581059 | Efficacy of Ginseng for Patients on Regorafenib | terminated | Phase 2 | 10 | Wake Forest University Health SciencesOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 49 | PfizerINDUSTRY | 1 | Jun 26, 2024 | clinicaltrials |
| NCT05609656 | Electroporation and Immunotherapy in Metastatic Colorectal Cancer(ELI) | terminated | Phase 2 | 4 | Ismail GögenurOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT03730948 | DC Vaccine in Colorectal Cancer | terminated | Phase 1 | 4 | University of PennsylvaniaOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT03300544 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer | terminated | Phase 1 | 3 | National Cancer Institute (NCI)NIH | 1 | May 23, 2024 | clinicaltrials |
| NCT06164691 | Blue and Amber Light Exposure in Patients With Rectal and Pancreatic Cancer | terminated | N/A | 2 | Matthew Neal MDOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT04718610 | Heart Rate Variability, Vagus Nerve and Cancer | terminated | N/A | 25 | Centre Hospitalier Henri Duffaut - AvignonOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT05732233 | RITUAL Ultivision AI CADe Randomized Controlled Trial(RITUAL) | terminated | N/A | 137 | Satisfai Health, Inc.INDUSTRY | 3 | May 13, 2024 | clinicaltrials |
| NCT04073615 | A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC) | terminated | Phase 1 | 29 | Elevar TherapeuticsINDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT05648006 | First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer | terminated | Phase 2 | 7 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT00838578 | Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 65 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT04808362 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours(MYCure) | terminated | Phase 1 / Phase 2 | 22 | Peptomyc S.L.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT03402477 | "Watch and Wait" After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal Cancer.(NORWAIT) | terminated | — | 86 | Helse Stavanger HFOTHER_GOV | 1 | Apr 24, 2024 | clinicaltrials |
| NCT04731441 | Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact | terminated | N/A | 12 | Milton S. Hershey Medical CenterOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT02293811 | Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa(P2RX7) | terminated | N/A | 50 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT04172597 | A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies | terminated | Phase 2 | 1 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | terminated | Phase 1 / Phase 2 | 11 | NKGen Biotech, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT04812743 | Colorectal Health Research Champions | terminated | N/A | 91 | Virginia Commonwealth UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT01605318 | Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 92 | Gilead SciencesINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03500874 | Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM | terminated | Phase 3 | 92 | Sun Yat-sen UniversityOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT03806244 | Feasibility of Stereotactic Navigation in Laparoscopic Surgery for Colorectal Cancer(PELVINAV) | terminated | N/A | 12 | IHU StrasbourgOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT04097795 | Incremental Cost-Utility Study on Prehabilitation Among Older Patients With Colorectal Cancer Undergoing Surgery(PreColo CU) | terminated | — | 72 | Radboud University Medical CenterOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT01133990 | FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 5 | Eisai Inc.INDUSTRY | 5 | Nov 7, 2023 | clinicaltrials |
| NCT03555149 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | terminated | Phase 1 / Phase 2 | 96 | Hoffmann-La RocheINDUSTRY | 5 | Nov 7, 2023 | clinicaltrials |
| NCT04623515 | Radiation Therapy on Pelvic Floor Disorders in Women(RadPFD) | terminated | — | 49 | Wake Forest University Health SciencesOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04854434 | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | terminated | Phase 2 | 13 | Karyopharm Therapeutics IncINDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT01545141 | Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer | terminated | Phase 1 / Phase 2 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT02626377 | Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté(ICE) | terminated | N/A | 186 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT00006046 | Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer | terminated | Phase 1 | 7 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating Patients With Rectal Cancer | terminated | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2024source: clinicaltrials